Latest filing published 15 Nov 2024 for EQL Pharma AB, €52k.
Filing timeline
BuySaleInsider track record
Closed purchases
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
Carl Lindgren: trading record in brief
Carl Lindgren discloses dealings in EQL Pharma AB to Finansinspektionen. Between 31 August 2023 and 14 November 2024, the trades on record add up to 3 filings.
The open-market record is one-sided, with 3 purchases worth €198k and not one sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. 2024 to date brings 1 purchase and no sales.
Half of the purchases are above €52k and half below.
The newest entry dates from 15 November 2024: an open-market purchase of €52k, in EQL Pharma AB. Between a trade and the moment it shows up on Finansinspektionen, the median delay is 1 day. For comparison, MAR article 19 gives managers three business days to notify a trade. Source: insider filings from Finansinspektionen. Past trades are no guide to future returns.
Companies and markets linked to Carl Lindgren
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 10,000 shares@ SEK 60.0026.1% of flowAktieISIN SE0005497732FI:csv-068c4f37f800318d2e6fCanonical exit: 12 Feb 2025 (T+90)
- 50,000 shares@ SEK 30.0066.4% of flowAktieISIN SE0005497732FI:csv-e6f25282deb7dfdb7eacCanonical exit: 21 Feb 2024 (T+90)
- 100,000 shares@ SEK 1.777.5% of flowTeckningsoptionISIN SE0005497732FI:csv-f61d4ea68c411154c10fCanonical exit: 29 Nov 2023 (T+90)
3 of 3 declarations